Susceptibility of clinical isolates of novel pathogen Stenotrophomonas sepilia to novel benzoquinolizine fluoroquinolone levonadifloxacin.

IF 3.7 Q2 INFECTIOUS DISEASES JAC-Antimicrobial Resistance Pub Date : 2024-08-21 eCollection Date: 2024-08-01 DOI:10.1093/jacamr/dlae130
Surajit Chakraborty, Nishant Shekhar, Lipika Singhal, Rajneesh Singh Rawat, Ajay Duseja, Rahul K Verma, Kanika Bansal, Ivneet Kour, Sanjay Biswas, Ekadashi Rajni, Suneeta Sahu, Prabhu B Patil, Vikas Gautam
{"title":"Susceptibility of clinical isolates of novel pathogen <i>Stenotrophomonas sepilia</i> to novel benzoquinolizine fluoroquinolone levonadifloxacin.","authors":"Surajit Chakraborty, Nishant Shekhar, Lipika Singhal, Rajneesh Singh Rawat, Ajay Duseja, Rahul K Verma, Kanika Bansal, Ivneet Kour, Sanjay Biswas, Ekadashi Rajni, Suneeta Sahu, Prabhu B Patil, Vikas Gautam","doi":"10.1093/jacamr/dlae130","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong><i>Stenotrophomonas sepilia</i>, identified in 2021, is part of the <i>Stenotrophomonas maltophilia</i> complex (Smc) and shares high genomic identity with <i>S. maltophilia</i>. Resistance to levofloxacin, the recommended fluoroquinolone for <i>S. maltophilia</i>, is being increasingly reported. Recent studies indicate that levonadifloxacin, a novel benzoquinolizine, may be more effective. This study evaluates the antimicrobial efficacy of levofloxacin and levonadifloxacin against clinical isolates of <i>S. sepilia</i>.</p><p><strong>Objectives: </strong>To assess the antibacterial effectiveness of levofloxacin and levonadifloxacin against novel pathogen <i>S. sepilia.</i></p><p><strong>Methods: </strong>A total of 116 <i>S. maltophilia</i> isolates, identified by MALDI-TOF MS, were collected from five centres across India. <i>S. sepilia</i> was confirmed by PCR using primers targeting a unique genomic sequence (NCBI accession number LXXZ00000000.1). Minimum inhibitory concentrations (MICs) of levonadifloxacin and levofloxacin were determined by using the microbroth-dilution method and Etest as per CLSI guidelines. The levofloxacin breakpoint was used to interpret MICs of levonadifloxacin.</p><p><strong>Results: </strong>Among a total of 116 circulating <i>S. maltophilia</i> isolates collected, 46 were identified as <i>S. sepilia</i>, representing a prevalence rate of (∼40%), thus highlighting its significance as an important pathogen within the Smc. Both levofloxacin and levonadifloxacin demonstrated a 98% inhibition rate against the 46 <i>S. sepilia</i> tested. Only one <i>S. sepilia</i> isolate resistant to levofloxacin showed intermediate susceptibility to levonadifloxacin, which consistently had lower MICs.</p><p><strong>Conclusions: </strong>Levofloxacin and levonadifloxacin show similar susceptibility rates against <i>S. sepilia</i>, with levonadifloxacin exhibiting lower MICs. Further studies are required to establish clinical utility of levonadifloxacin in managing these infections.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11337124/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAC-Antimicrobial Resistance","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/jacamr/dlae130","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Stenotrophomonas sepilia, identified in 2021, is part of the Stenotrophomonas maltophilia complex (Smc) and shares high genomic identity with S. maltophilia. Resistance to levofloxacin, the recommended fluoroquinolone for S. maltophilia, is being increasingly reported. Recent studies indicate that levonadifloxacin, a novel benzoquinolizine, may be more effective. This study evaluates the antimicrobial efficacy of levofloxacin and levonadifloxacin against clinical isolates of S. sepilia.

Objectives: To assess the antibacterial effectiveness of levofloxacin and levonadifloxacin against novel pathogen S. sepilia.

Methods: A total of 116 S. maltophilia isolates, identified by MALDI-TOF MS, were collected from five centres across India. S. sepilia was confirmed by PCR using primers targeting a unique genomic sequence (NCBI accession number LXXZ00000000.1). Minimum inhibitory concentrations (MICs) of levonadifloxacin and levofloxacin were determined by using the microbroth-dilution method and Etest as per CLSI guidelines. The levofloxacin breakpoint was used to interpret MICs of levonadifloxacin.

Results: Among a total of 116 circulating S. maltophilia isolates collected, 46 were identified as S. sepilia, representing a prevalence rate of (∼40%), thus highlighting its significance as an important pathogen within the Smc. Both levofloxacin and levonadifloxacin demonstrated a 98% inhibition rate against the 46 S. sepilia tested. Only one S. sepilia isolate resistant to levofloxacin showed intermediate susceptibility to levonadifloxacin, which consistently had lower MICs.

Conclusions: Levofloxacin and levonadifloxacin show similar susceptibility rates against S. sepilia, with levonadifloxacin exhibiting lower MICs. Further studies are required to establish clinical utility of levonadifloxacin in managing these infections.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
新型病原体败血霉单胞菌临床分离株对新型苯喹嗪类氟喹诺酮左氧氟沙星的敏感性。
背景:嗜血杆菌于2021年被发现,是嗜麦芽僵单胞菌复合体(Smc)的一部分,与嗜麦芽僵单胞菌的基因组具有高度的同一性。对嗜麦芽单胞菌推荐使用的氟喹诺酮类药物左氧氟沙星产生抗药性的报道越来越多。最近的研究表明,新型苯醌利嗪类药物左氧氟沙星可能更有效。本研究评估了左氧氟沙星和左氧氟沙星对嗜血杆菌临床分离株的抗菌效果:评估左氧氟沙星和左氧氟沙星对新型病原体麦芽糖酵母菌的抗菌效果:方法:通过 MALDI-TOF MS 鉴定,从印度的 5 个中心共收集到 116 株嗜麦芽沙雷氏菌分离株。使用针对独特基因组序列(NCBI登录号为 LXXZ00000000.1)的引物通过 PCR 鉴定确认了嗜麦芽酵母菌。左氧氟沙星和左氧氟沙星的最低抑菌浓度(MICs)是根据 CLSI 指南,采用微流稀释法和 Etest 法测定的。用左氧氟沙星断点来解释左氧氟沙星的 MICs:结果:在收集到的 116 个嗜麦芽糖酵母菌循环分离株中,有 46 个被鉴定为嗜脓酵母菌,流行率为(∼40%),从而凸显了其作为 Smc 中重要病原体的重要性。左氧氟沙星和左氧氟沙星对测试的 46 个塞氏菌的抑制率均为 98%。只有一个对左氧氟沙星耐药的脓血吸虫分离株对左氧氟沙星表现出中间易感性,而左氧氟沙星的 MIC 值一直较低:结论:左氧氟沙星和左氧氟沙星对塞普氏菌的敏感率相似,左氧氟沙星的 MIC 值更低。要确定左氧氟沙星在治疗这些感染中的临床效用,还需要进一步的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.30
自引率
0.00%
发文量
0
审稿时长
16 weeks
期刊最新文献
Outcomes of Enterococcus faecalis infective endocarditis according to MIC of amoxicillin: a multicentric study. Experience with expanded use of oritavancin in a tertiary hospital: indications, tolerability and outcomes. Antimicrobial use in hospitalized patients: a point prevalence survey across four tertiary hospitals in Niger. Aetiology, susceptibility and outcomes of fever in patients receiving chemotherapy in Malawi: a prospective study. Community pharmacists' knowledge and practices towards antimicrobial stewardship: findings and implications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1